OtherAug 21, 2026Pending
🇺🇸 United States
WTWerewolf Therapeutics, Inc.ATAmbros Therapeutics, Inc.
Healthcare › Pharmaceuticals
Equity value$47.5MEquity value
AnnouncedAug 21, 2026
ConsiderationStock
StructureOne-step merger
RegionNorth America
Cross-borderNo
Contingent paymentYes
Overview
Ambros Therapeutics agreed to a reverse merger with Werewolf Therapeutics in an all-stock transaction, with the exchange ratio based on an implied value of $500 million for Ambros and $47.5 million for Werewolf. Werewolf stockholders also receive a contingent value right tied to proceeds from dispositions of legacy assets.
Deal rationale
The merger gives Werewolf a late-stage asset, neridronate for CRPS-1, and a concurrent $150 million private placement to fund the combined company through Phase 3 results.
AI-generated from the SEC filingPendingHealthcare › PharmaceuticalsUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | $47.5M | Headline figure |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Stock |
Advisors
Buy-side
None listed
Sell-side
PSPiper Sandler
Parties
Target
WTWerewolf Therapeutics, Inc.
- Headquarters
- United States
- Ticker
- HOWL
Acquirer
ATAmbros Therapeutics, Inc.
- Headquarters
- United States
- Ticker
- —